Abstract
Background
Rituximab (RTX) provides significant clinical benefits in active rheumatoid arthritis (RA) patients with inadequate response to DMARDs and anti-TNF. There is no data regarding efficacy of RTX in seropositive Palindromic Rheumatism (PR), a forerunner of RA.
Aim
To determine the efficacy and safety of RTX treatment in active PR patients exhibiting inadequate response to conventional synthetic DMARDs (csDMARDs).
Methods
The retrospective study, over a period of 3 years, included seropositive (RF ± antiCCP) PR patients with inadequate control of PR (> 4 attacks per months) despite combination csDMARDs and were treated with RTX. All the patients were treated with an initial dose of 500 mg RTX and later with a second infusion after 2 weeks’ period in those who did not achieve adequate/ complete disease control. Patients were continued on csDMARDS and retreated with RTX on relapse of symptoms.
Results
Thirty-three seropositive PR patients with a mean age of 48.15 ± 14.2 years, mean disease duration of 68.4 ± 68.2 months, mean follow up period of 24.3 ± 10.8 months, were treated with RTX. 88% patients were on combination DMARDS and 79% patients were females. All patient achieved rapid and complete control of palindromic attacks with RTX. Fifteen patients had a relapse after a mean duration of 10.4 ± 5.5 months and needed repeat RTX infusions following which remission was achieved. None of the patients progressed to RA till the end of the follow-up. No serious adverse effects were recorded.
Conclusion
RTX treatment could be effective in achieving disease control in active palindromic rheumatism not responding to csDMARDs.
Key Points
• PR is thought to be a forerunner of RA and rituximab (RTX) has been found to be effective in RA.
• Our study supports the hypothesis that B cells play an important role in the pathophysiology of PR and that the combination (RTX+ conventional drugs) can prevent the disease evolution into RA.
• This 3-year retrospective study showed that rituximab was found to be effective in those who responded poorly to conventional drugs and remission was achieved in all patients.
• Although it is a rare disease, we see palindromic rheumatism patients in India more often. As the symptoms are very debilitating in these patients, in those patients, not controlled on conventional drugs, rituximab offers newer promise in controlling the attacks and prevents further progression to RA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wajed MA, Brown DL, Currey HL (1977) Palindromic rheumatism. Clinical and serum complement study. Ann Rheum Dis 36(1):56–61
Guerne PA, Weisman MH (1992) Palindromic rheumatism: part of or apart from the spectrum of rheumatoid arthritis. Am J Med 93(4):451–460
Hannonen P, Mottonen T, Oka M (1987) Palindromic rheumatism. A clinical survey of sixty patients. Scand J Rheumatol 16:413e20
Golding DN (1988) Sulphasalazine for palindromic rheumatism. Br J Rheumatol 27:79
Youssef W, Yan A, Russell AS (1991) Palindromic rheumatism: a response to chloroquine. J Rheumatol 18:35e7
Gonzalez-Lopez L, Gamez-Nava JI, Jhangri G et al (2000) Decreased progression to rheumatoid arthritis or other connective tissue diseases in patients with palindromic rheumatism treated with antimalarials. J Rheumatol 27:41e6
Wendler J, Burmester GR, Sörensen H, Krause A, Richter C, Tony HP, Rubbert-Roth A, Bartz-Bazzanella P, Wassenberg S, Haug-Rost I, Dörner T (2014) Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients. Arthritis Res Ther 16(2):R80
Mok CC (2014) Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Dev Ther 8:87
Edwards JC, Szczepański L, Szechiński J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350(25):2572–2581
Hannonen P, Müttönen T, Oka M (1987) Palindromic rheumatism: a clinical survey of sixty patients. Scand J Rheumatol 16(6):413–420
Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T (2011) Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 1:annrheumdis–annrheu2010
Youssef WA, Yan AL, Russell AS (1991) Palindromic rheumatism: a response to chloroquine. J Rheumatol 18(1):35–37
Mankia K, Emery P (2017) What can palindromic rheumatism tell us? Best Pract Res Clin Rheumatol 31(1):90–98
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Raghavan, P., Sreenath, S., Cherian, S. et al. Efficacy of rituximab in resistant palindromic rheumatism: first report in literature. Clin Rheumatol 38, 2399–2402 (2019). https://doi.org/10.1007/s10067-019-04578-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-019-04578-2